Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union
The development of second-entry topical products is hampered by several factors. The excipient composition should be similar to the reference product because excipients may also contribute to efficacy. Conventional pharmacokinetic bioequivalence studies were not considered acceptable because drug co...
Main Authors: | Alfredo García-Arieta, John Gordon, Luther Gwaza, Virginia Merino, Víctor Mangas-Sanjuan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/2/601 |
Similar Items
-
Influence of Inter- and Intra-Batch Variability on the Sample Size Required for Demonstration of Equivalent Microstructure of Semisolid Dosage Forms
by: Zhengguo Xu, et al.
Published: (2020-11-01) -
Assessment of the Inter-Batch Variability of Microstructure Parameters in Topical Semisolids and Impact on the Demonstration of Equivalence
by: Víctor Mangas-Sanjuán, et al.
Published: (2019-10-01) -
Topical Amphotericin B Semisolid Dosage Form for Cutaneous Leishmaniasis: Physicochemical Characterization, Ex Vivo Skin Permeation and Biological Activity
by: Diana Berenguer, et al.
Published: (2020-02-01) -
Estimation of Topic Similarity and Its Application to Measuring Stability of Topic Modeling
by: Sung-Chien Lin
Published: (2022-07-01) -
Complying with the Guideline for Quality and Equivalence for Topical Semisolid Products: The Case of Clotrimazole Cream
by: Teresa Alves, et al.
Published: (2021-04-01)